Longeveron To Host Key Opinion Leader Event On Medicinal Signaling Cells (MSCs) For Hypoplastic Left Heart Syndrome (HLHS) With Lomecel-B™ On August 16, 2023
MIAMI, August 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it will host a virtual KOL Event on August 16, 2023 at 10:00 AM ET.